Kane publishes article in International Wound Journal

Executive Summary

• Kane Biotech announced the publication of a peer-reviewed article in the International Wound Journal regarding its revyve anti-microbial wound gel.
• The study validates the gel's thermo-reversible properties, demonstrating efficacy against broad-spectrum pathogens and sustained in vitro activity.
• The publication serves as independent, peer-reviewed validation of the technology's safety and clinical potential, aimed at strengthening credibility with regulators and commercial partners.

Key Details

• Publication Details: Article titled "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity" published in the International Wound Journal.
• Lead Author: Dr. Jeyachchandran Visvalingam (Internal R&D leader at Kane Biotech), with co-authors from the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami.
• Product Mechanism: The thermo-reversible gel shifts from a low-viscosity liquid to a form-fitting gel at body temperature and reliquefies when cooled, allowing for easy, atraumatic removal.
• Antimicrobial Efficacy: Demonstrated efficacy against a broad range of wound-related pathogens, specifically Staphylococcus aureus and Pseudomonas aeruginosa.
• Bacterial Reduction: Achieved a 99.99% to 99.9999% reduction in bacterial counts within 30 minutes.
• Sustained Activity: Showed sustained in vitro activity for up to seven days, which may potentially reduce the frequency of dressing changes.
• Safety Validation: Safety and non-cytotoxicity were validated through biocompatibility testing and a porcine wound-healing study.
• Regulatory Status: revyve anti-microbial wound gel is U.S. FDA 510(k)-cleared and Health Canada-approved.

Notable Quotes

• "Having our research published in the International Wound Journal underscores the scientific rigour behind revyve technology and provides independent, peer-reviewed validation of the gel's safety, in vitro performance and clinical potential," said Dr. Robert Huizinga, interim chief executive officer. "Recognition in such a respected global wound-care publication strengthens our credibility with clinicians, regulators and commercial partners and reinforces our commitment to advancing evidence-based solutions that improve patient outcomes."